All anti-CD20 monoclonal antibodies have similar efficacy and risks: No

Finn Sellebjerg*, Jeppe Romme Christensen

*Corresponding author for this work
Original languageEnglish
JournalMultiple Sclerosis Journal
Volume28
Issue number12
Pages (from-to)1845-1846
Number of pages2
ISSN1352-4585
DOIs
Publication statusPublished - Oct 2022

Keywords

  • Antibodies, Monoclonal/therapeutic use
  • Antineoplastic Agents
  • Humans

Cite this